TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
Follow-Up Questions
Who is the CEO of TuHURA Biosciences Inc?
Mr. James Bianco is the Chief Executive Officer of TuHURA Biosciences Inc, joining the firm since 2024.
What is the price performance of HURA stock?
The current price of HURA is $2.55, it has decreased 1.16% in the last trading day.
What are the primary business themes or industries for TuHURA Biosciences Inc?
TuHURA Biosciences Inc belongs to Biotechnology industry and the sector is Health Care
What is TuHURA Biosciences Inc market cap?
TuHURA Biosciences Inc's current market cap is $127.6M
Is TuHURA Biosciences Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for TuHURA Biosciences Inc, including 2 strong buy, 6 buy, 1 hold, 0 sell, and 2 strong sell
